

DS01

Striking off application by a company



Companies House

A fee is payable with this form
Please see 'How to pay' on the last page.

☒ What this form is for
You may use this form to strike off a
company from the Register.

☐ What this form is for
You cannot use this form to strike off a Limited Liability Partnership (LLP). To strike off a Limited Liability Partnership (LLP), you must use form LL DS01 'Striking off application by a Limited Liability Partnership (LLP)'.

SATURDAY



S1NUG7U2

SCT

15/12/2012

#326

COMPANIES HOUSE

please

gov.uk

Warning to all interested parties

This is an important notice and should not be ignored. The company named has applied to the Registrar to be struck off the Register and dissolved. Please note that on dissolution any remaining assets will be passed to the Crown. The Registrar will strike the company off the register unless there is reasonable cause not to do so. Guidance is available on grounds for objection. If in doubt, seek professional advice.

1

Company details

Company number S C 3 4 5 0 8 0

Company name in full Acacia Environmental Ltd

→ Filling in this form
Please complete in typescript or in
bold black capitals.

All fields are mandatory unless
specified or indicated by *

2

The application

Warning to all applicants

It is an offence to knowingly or recklessly provide false or misleading information on this application.

You are advised to read Section 4 and to consult the guidance available from Companies House before completing this form. If in doubt, seek professional advice.

I/We as director(s) / the majority of directors apply for this company to be struck off the Register and declare that none of the circumstances described in section 1004 or 1005 of the Companies Act 2006 (being circumstances in which the directors would otherwise be prohibited under those sections from making an application) exists in relation to the company.①

This form must be signed by the sole director if only 1, by both if there are 2, or by the majority if there are more than 2.

→ Go to Section 3 'Name(s) and Signature(s) of the directors'

① Please read the guidance on our website at www.companieshouse.gov.uk or section 1004 or 1005 of the Companies Act 2006 for circumstances under which an application may not be made.

Please note that on dissolution all property and rights etc will be passed to the Crown.

The first part of the paper discusses the theoretical background of the study. It covers the basic concepts and definitions related to the research topic. The second part of the paper describes the methodology used in the study. It includes details about the data collection process, the sample size, and the statistical methods employed.

The third part of the paper presents the results of the study. It includes a detailed description of the data and the statistical analysis. The fourth part of the paper discusses the implications of the findings and provides conclusions.

The fifth part of the paper discusses the limitations of the study and suggests areas for future research. The sixth part of the paper provides a summary of the findings and a final conclusion.

The seventh part of the paper discusses the implications of the findings and provides conclusions. The eighth part of the paper provides a summary of the findings and a final conclusion.

The ninth part of the paper discusses the implications of the findings and provides conclusions. The tenth part of the paper provides a summary of the findings and a final conclusion.

The eleventh part of the paper discusses the implications of the findings and provides conclusions. The twelfth part of the paper provides a summary of the findings and a final conclusion.

The thirteenth part of the paper discusses the implications of the findings and provides conclusions. The fourteenth part of the paper provides a summary of the findings and a final conclusion.

The fifteenth part of the paper discusses the implications of the findings and provides conclusions. The sixteenth part of the paper provides a summary of the findings and a final conclusion.

The seventeenth part of the paper discusses the implications of the findings and provides conclusions. The eighteenth part of the paper provides a summary of the findings and a final conclusion.

The nineteenth part of the paper discusses the implications of the findings and provides conclusions. The twentieth part of the paper provides a summary of the findings and a final conclusion.

The twenty-first part of the paper discusses the implications of the findings and provides conclusions. The twenty-second part of the paper provides a summary of the findings and a final conclusion.

The twenty-third part of the paper discusses the implications of the findings and provides conclusions. The twenty-fourth part of the paper provides a summary of the findings and a final conclusion.

The twenty-fifth part of the paper discusses the implications of the findings and provides conclusions. The twenty-sixth part of the paper provides a summary of the findings and a final conclusion.

The twenty-seventh part of the paper discusses the implications of the findings and provides conclusions. The twenty-eighth part of the paper provides a summary of the findings and a final conclusion.

The twenty-ninth part of the paper discusses the implications of the findings and provides conclusions. The thirtieth part of the paper provides a summary of the findings and a final conclusion.

DS01

Striking off application by a company

3 Name(s) and signature(s) of the director(s)

Name (Print clearly)	Katie Martin											
Signature	X <i>Katie Martin</i> X											
Signature date	d	0	4	m	1	2	y	2	0	1	2	
Name (Print clearly)												
Signature	X X											
Signature date	d			m			y					
Name (Print clearly)												
Signature	X X											
Signature date	d			m			y					
Name (Print clearly)												
Signature	X X											
Signature date	d			m			y					

Warning to all applicants
It is an offence to knowingly or recklessly provide false or misleading information on this application.

Please note that on dissolution all property and rights etc will be passed to the Crown.

You are advised to read Section 4 and to consult the guidance notes available from Companies House before completing this form. If in doubt, seek professional advice.

Name and date
Please ensure that you complete the name and signature date

Signatures
This form must be signed by the sole director if only 1, by both if there are 2, or by the majority if there are more than 2.

Further signatures
Please use a continuation page if you need to enter further signatures.

4 What to do next**Notify all parties.**

Please ensure that you send copies of this application to all notifiable parties e.g. creditors, employees, shareholders, pension managers or trustees and other directors of the company within 7 days from the day on which the application is made.

Please also send copies to anyone who later becomes a notifiable party within 7 days of this taking place. This applies from the day of application and before the day on which the application is finally dealt with or withdrawn. Please check the guidance notes which contain a full list of those who must be notified. Failure to notify interested parties is an offence. It is advisable to obtain and retain some proof of delivery or posting of copies to notifiable parties.

Withdrawal of striking off application by a company

If the company ceases to be eligible for striking off at any time after the application is made, and before the application is finally dealt with, as specified in section 1009 of the Companies Act 2006, then the application must be withdrawn using form DS02 'Withdrawal of striking off application by a company' available from our website: www.companieshouse.gov.uk

...and the other is the fact that the

1. *Pharmaceuticals* (1997) 10, 115-120.
 2. *Pharmaceuticals* (1997) 10, 121-126.
 3. *Pharmaceuticals* (1997) 10, 127-132.
 4. *Pharmaceuticals* (1997) 10, 133-138.
 5. *Pharmaceuticals* (1997) 10, 139-144.
 6. *Pharmaceuticals* (1997) 10, 145-150.
 7. *Pharmaceuticals* (1997) 10, 151-156.
 8. *Pharmaceuticals* (1997) 10, 157-162.
 9. *Pharmaceuticals* (1997) 10, 163-168.
 10. *Pharmaceuticals* (1997) 10, 169-174.
 11. *Pharmaceuticals* (1997) 10, 175-180.
 12. *Pharmaceuticals* (1997) 10, 181-186.
 13. *Pharmaceuticals* (1997) 10, 187-192.
 14. *Pharmaceuticals* (1997) 10, 193-198.
 15. *Pharmaceuticals* (1997) 10, 199-204.
 16. *Pharmaceuticals* (1997) 10, 205-210.
 17. *Pharmaceuticals* (1997) 10, 211-216.
 18. *Pharmaceuticals* (1997) 10, 217-222.
 19. *Pharmaceuticals* (1997) 10, 223-228.
 20. *Pharmaceuticals* (1997) 10, 229-234.
 21. *Pharmaceuticals* (1997) 10, 235-240.
 22. *Pharmaceuticals* (1997) 10, 241-246.
 23. *Pharmaceuticals* (1997) 10, 247-252.
 24. *Pharmaceuticals* (1997) 10, 253-258.
 25. *Pharmaceuticals* (1997) 10, 259-264.
 26. *Pharmaceuticals* (1997) 10, 265-270.
 27. *Pharmaceuticals* (1997) 10, 271-276.
 28. *Pharmaceuticals* (1997) 10, 277-282.
 29. *Pharmaceuticals* (1997) 10, 283-288.
 30. *Pharmaceuticals* (1997) 10, 289-294.
 31. *Pharmaceuticals* (1997) 10, 295-300.
 32. *Pharmaceuticals* (1997) 10, 301-306.
 33. *Pharmaceuticals* (1997) 10, 307-312.
 34. *Pharmaceuticals* (1997) 10, 313-318.
 35. *Pharmaceuticals* (1997) 10, 319-324.
 36. *Pharmaceuticals* (1997) 10, 325-330.
 37. *Pharmaceuticals* (1997) 10, 331-336.
 38. *Pharmaceuticals* (1997) 10, 337-342.
 39. *Pharmaceuticals* (1997) 10, 343-348.
 40. *Pharmaceuticals* (1997) 10, 349-354.
 41. *Pharmaceuticals* (1997) 10, 355-360.
 42. *Pharmaceuticals* (1997) 10, 361-366.
 43. *Pharmaceuticals* (1997) 10, 367-372.
 44. *Pharmaceuticals* (1997) 10, 373-378.
 45. *Pharmaceuticals* (1997) 10, 379-384.
 46. *Pharmaceuticals* (1997) 10, 385-390.
 47. *Pharmaceuticals* (1997) 10, 391-396.
 48. *Pharmaceuticals* (1997) 10, 397-402.
 49. *Pharmaceuticals* (1997) 10, 403-408.
 50. *Pharmaceuticals* (1997) 10, 409-414.
 51. *Pharmaceuticals* (1997) 10, 415-420.
 52. *Pharmaceuticals* (1997) 10, 421-426.
 53. *Pharmaceuticals* (1997) 10, 427-432.
 54. *Pharmaceuticals* (1997) 10, 433-438.
 55. *Pharmaceuticals* (1997) 10, 439-444.
 56. *Pharmaceuticals* (1997) 10, 445-450.
 57. *Pharmaceuticals* (1997) 10, 451-456.
 58. *Pharmaceuticals* (1997) 10, 457-462.
 59. *Pharmaceuticals* (1997) 10, 463-468.
 60. *Pharmaceuticals* (1997) 10, 469-474.
 61. *Pharmaceuticals* (1997) 10, 475-480.
 62. *Pharmaceuticals* (1997) 10, 481-486.
 63. *Pharmaceuticals* (1997) 10, 487-492.
 64. *Pharmaceuticals* (1997) 10, 493-498.
 65. *Pharmaceuticals* (1997) 10, 499-504.
 66. *Pharmaceuticals* (1997) 10, 505-510.
 67. *Pharmaceuticals* (1997) 10, 511-516.
 68. *Pharmaceuticals* (1997) 10, 517-522.
 69. *Pharmaceuticals* (1997) 10, 523-528.
 70. *Pharmaceuticals* (1997) 10, 529-534.
 71. *Pharmaceuticals* (1997) 10, 535-540.
 72. *Pharmaceuticals* (1997) 10, 541-546.
 73. *Pharmaceuticals* (1997) 10, 547-552.
 74. *Pharmaceuticals* (1997) 10, 553-558.
 75. *Pharmaceuticals* (1997) 10, 559-564.
 76. *Pharmaceuticals* (1997) 10, 565-570.
 77. *Pharmaceuticals* (1997) 10, 571-576.
 78. *Pharmaceuticals* (1997) 10, 577-582.
 79. *Pharmaceuticals* (1997) 10, 583-588.
 80. *Pharmaceuticals* (1997) 10, 589-594.
 81. *Pharmaceuticals* (1997) 10, 595-600.
 82. *Pharmaceuticals* (1997) 10, 601-606.
 83. *Pharmaceuticals* (1997) 10, 607-612.
 84. *Pharmaceuticals* (1997) 10, 613-618.
 85. *Pharmaceuticals* (1997) 10, 619-624.
 86. *Pharmaceuticals* (1997) 10, 625-630.
 87. *Pharmaceuticals* (1997) 10, 631-636.
 88. *Pharmaceuticals* (1997) 10, 637-642.
 89. *Pharmaceuticals* (1997) 10, 643-648.
 90. *Pharmaceuticals* (1997) 10, 649-654.
 91. *Pharmaceuticals* (1997) 10, 655-660.
 92. *Pharmaceuticals* (1997) 10, 661-666.
 93. *Pharmaceuticals* (1997) 10, 667-672.
 94. *Pharmaceuticals* (1997) 10, 673-678.
 95. *Pharmaceuticals* (1997) 10, 679-684.
 96. *Pharmaceuticals* (1997) 10, 685-690.
 97. *Pharmaceuticals* (1997) 10, 691-696.
 98. *Pharmaceuticals* (1997) 10, 697-702.
 99. *Pharmaceuticals* (1997) 10, 703-708.
 100. *Pharmaceuticals* (1997) 10, 709-714.
 101. *Pharmaceuticals* (1997) 10, 715-720.
 102. *Pharmaceuticals* (1997) 10, 721-726.
 103. *Pharmaceuticals* (1997) 10, 727-732.
 104. *Pharmaceuticals* (1997) 10, 733-738.
 105. *Pharmaceuticals* (1997) 10, 739-744.
 106. *Pharmaceuticals* (1997) 10, 745-750.
 107. *Pharmaceuticals* (1997) 10, 751-756.
 108. *Pharmaceuticals* (1997) 10, 757-762.
 109. *Pharmaceuticals* (1997) 10, 763-768.
 110. *Pharmaceuticals* (1997) 10, 769-774.
 111. *Pharmaceuticals* (1997

100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%

$$f_{\text{max}} = \frac{1}{2\pi} \sqrt{\frac{1}{L C_{\text{eff}}}} = \frac{1}{2\pi} \sqrt{\frac{1}{L (C_1 + C_2)}} = \frac{1}{2\pi} \sqrt{\frac{1}{L C_1 (1 + \frac{C_2}{C_1})}} = \frac{1}{2\pi} \sqrt{\frac{1}{L C_1}} \frac{1}{\sqrt{1 + \frac{C_2}{C_1}}} = f_{\text{max0}} \frac{1}{\sqrt{1 + \frac{C_2}{C_1}}} \quad (1)$$

DS01

Striking off application by a company



Presenter information

You do not have to give any contact information, but if you do it will help Companies House if there is a query on the form. The contact information you give will be visible to searchers of the public record.

Contact name

Company name

Address

Post town

County/Region

Postcode

Country

DX

Telephone



Checklist

We may return the forms completed incorrectly or with information missing.

Please make sure you have remembered the following:

- ☐ The company name and number match the information held on the public Register.
- ☐ The correct number of current directors have signed and dated the form – 1 director if there is only 1 director, both if there are 2, and the majority if there are more than 2 e.g. Out of 6 directors, 4 must sign.
- ☐ You have included a printed name and date for the signature(s)
- ☐ You have included a continuation sheet (available from www.companieshouse.gov.uk) if applicable.
- ☐ You have enclosed the correct fee.



Important information

Please note that all information on this form will appear on the public record.



How to pay

A fee of £10 is payable to Companies House in respect of a striking off application.

Make cheques or postal orders payable to 'Companies House.'



Where to send

You may return this form to any Companies House address, however for expediency we advise you to return it to the appropriate address below:

For companies registered in England and Wales:
The Registrar of Companies, Companies House,
Crown Way, Cardiff, Wales, CF14 3UZ.
DX 33050 Cardiff.

For companies registered in Scotland:
The Registrar of Companies, Companies House,
Fourth floor, Edinburgh Quay 2,
139 Fountainbridge, Edinburgh, Scotland, EH3 9FF.
DX ED235 Edinburgh 1
or LP - 4 Edinburgh 2 (Legal Post).

For companies registered in Northern Ireland:
The Registrar of Companies, Companies House,
Second Floor, The Linenhall, 32-38 Linenhall Street,
Belfast, Northern Ireland, BT2 8BG.
DX 481 N.R. Belfast 1.



Further information

For further information please see the guidance notes on the website at www.companieshouse.gov.uk or email enquiries@companieshouse.gov.uk

This form is available in an alternative format. Please visit the forms page on the website at www.companieshouse.gov.uk